NCT07163845View on ClinicalTrials.gov

Assessment of Chikungunya Virus Seroprevalence Before VLA1553 Vaccination in the Municipalities Selected for Participation in the VLA1553 Pilot Vaccination Strategy in Brazil

Enrolling by invitationOBSERVATIONAL
Enrollment

4,988

Participants

Timeline

Start Date

September 22, 2025

Primary Completion Date

December 15, 2025

Study Completion Date

December 31, 2026

Conditions
Chikungunya Virus Infection
Interventions
BIOLOGICAL

Live-attenuated CHIKV vaccine VLA1553

Non-interventional study: VLA1553 is used in the pilot vaccination strategy which is carried out after this observational study.

Trial Locations (4)

60430-160

Universidade Federal Do Ceará, Fortaleza

31270-901

Universidade Federal de Minas Gerais, CT Terapias Avançadas e Inovadoras, Belo Horizonte

49060-025

Centro de Pesquisas Clínicas Universidade Federal Sergipe, Hospital e Maternidade São João de Deus, Laranjeiras

15090-000

Fundação Faculdade Regional De Medicina De São José Do Rio Preto, São Pedro

All Listed Sponsors
collaborator

Fundação Butantan

UNKNOWN

collaborator

Coalition for Epidemic Preparedness Innovations

OTHER

lead

Valneva Austria GmbH

INDUSTRY